Screener
Denali Therapeutics Inc. DNLI Other operating expenses
Discontinued — last reported Q1 '26
Other operating expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001714899-26-000064
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $103,846 | $116,227 |
| General and administration | 33,511 | 29,353 |
| Total operating expenses | 137,357 | 145,580 |
| Loss from operations | (137,357) | (145,580) |
| Interest and other income, net | 8,910 | 12,610 |
| Net loss | $(128,447) | $(132,970) |
| Other comprehensive income (loss): |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s other operating expenses?
- Denali Therapeutics Inc. (DNLI) reported other operating expenses of $137.36M in Q1 2026.
- How has Denali Therapeutics Inc.'s other operating expenses changed year-over-year?
- Denali Therapeutics Inc.'s other operating expenses decreased by 5.6% year-over-year, from $145.58M to $137.36M.
- What is the long-term trend for Denali Therapeutics Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s other operating expenses has grown at a 12.7% compound annual growth rate (CAGR), from $344.41M to $555.34M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Denali Therapeutics Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude